Author:
Zhao Shu-Hua,Wang Yu,Wen Li,Zhai Zhen-Bo,Ai Zhen-Hua,Yao Nian-Ling,Wang Li,Liu Wen-Chao,Chen Bi-Liang,Li Yu,Yang Hong
Abstract
Abstract
Background
Basigin, which has four isoforms, has been demonstrated to be involved in progression of various human cancers. The aim of this study was to examine the prognostic value of basigin-2 protein expression in epithelial ovarian cancer. Furthermore, the function of basigin-2 in ovarian cancer was further investigated in cell culture models.
Methods
Immunohistochemistry staining was performed to investigate basigin-2 expression in a total of 146 ovarian tissue specimens. Kaplan Meier analysis and Cox proportional hazards model were applied to assess the relationship between basigin-2 and progression-free survival (PFS) and overall survival (OS). Real-time PCR, RT-PCR and western blot were used to explore basigin-2, basigin-3 and basigin-4 expression in ovarian cancer cell lines and tissues. To evaluate possible contributions of basigin-2 to MMP secretion and cell migration and invasion, the overexpression vectors pcDNA3.1-basigin-2 and basigin-2 siRNA were transfected into HO-8910 and HO-8910 PM cells respectively.
Results
High basigin-2 expression was associated with lymph-vascular space involvement, lymph node metastasis and poor prognosis of epithelial ovarian cancer. Multivariate analyses indicated that basigin-2 positivity was an independent prognostic factor for PFS (P = 0.006) and OS (P = 0.019), respectively. Overexpression of basigin-2 increased the secretion of MMP-2/9 and cancer cell migration and invasion of HO-8910 cells, whereas knockdown of basigin-2 reduced active MMP-2/9 production, migration and invasion of HO-8910 PM cells.
Conclusions
The expression of basigin-2 might be an independent prognostic marker and basigin-2 inhibition would be a potential strategy for epithelial ovarian cancer patients, especially in inhibiting and preventing cancer cell invasion and metastasis.
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference51 articles.
1. Permuth-Wey J, Sellers TA: Epidemiology of ovarian cancer. Methods Mol Biol. 2009, 472: 413-437. 10.1007/978-1-60327-492-0_20.
2. Wang M, He Y, Shi L, Shi C: Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer. Eur J Gynaecol Oncol. 2011, 32: 171-177.
3. Tung CS, Wong KK, Mok SC: Biomarker discovery in ovarian cancer. Womens Health. 2008, 4: 27-40.
4. Herzog TJ, Pothuri B: Ovarian cancer: a focus on management of recurrent disease. Nat Clin Pract Oncol. 2006, 3: 604-611.
5. Montero A, Fossella F, Hortobagyi G, Valero V: Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005, 6: 229-239. 10.1016/S1470-2045(05)70094-2.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献